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 Summary  
 
Title: Causes of elevated Troponin in Patients with Normal Coronary Angiography 
Keywords: Cardiac troponin, Angiographic coronary artery disease, Myocardial cell 
injury 
Author: Ana Reschner 
Troponin rise indicates myocardial cell injury. However, elevated values of troponin 
are not always consequence of infarction or ischemia.   
In this paper, aim was to elucidate diverse etiologies of elevated troponin in patients 
with normal coronary angiography.  
At KBC Zagreb in 2014 there was 976 patients identified from catheterization 
database who underwent coronary angiography due to suspicion of acute coronary 
syndrome (ACS). We identified 30 (3.1%) patients who had alternative cause for 
myocyte injury other than coronary artery disease (CAD), meaning that there was 
less than 30 % coronary arterial luminal stenosis.  
The elevation of cardiac troponin T (cTnT) in patients with normal coronary 
angiography was attributed to diverse etiologies, including hypertensive crisis, 
Takotsubo syndrome, severe aortic stenosis, atrial fibrillation (AF), chronic 
obstructive pulmonary disease (COPD) exacerbation, advanced heart failure, 
hypertensive cardiomyopathy, acute pulmonary embolism, malignant disease 
progression, and cardiogenic shock. 
Apart from ACS, cTnT could be elevated in a number of different conditions, which 
should be considered according to clinical presentation, different diagnostic 
procedure, and still could reflect myonecrosis, even in the absence of significant 
angiographic CAD. 
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1. INTRODUCTION 
 
Troponin is a complex which consists of three proteins: cTnC, cTnI and cTnT, which 
control skeletal and cardiac muscle contraction in response to intracellular calcium. 
Around 6-8% of cTnT and 2.8 – 8.3 % of cTnI are found free in the cytosol (1). Most 
commonly they are released as a result of proteolytic degradation. Initially Troponin 
is released from the cytoplasmic pool, following more release from quantities bound 
to deteriorating myofilaments (2).  
The measurement of serum cTnI and cTnT is superior in comparison to the 
measurement of cTnC in the identification of cardiac muscle damage in terms of 
sensitivity and specificity to cardiac muscle enzyme measurements (1).  
In peripheral blood, it takes 3-4 hours for cTnT to begin to rise after the onset of 
myocardial injury and remains increased for 10–14 days (3). 
Troponins are markers, which indicate presence of myocardial cell injury and 
necrosis but they do not indicate the mechanism causing it (4-7). Furthermore, 
ACC/AHA guidelines also indicate that the troponin elevation signifies   myocardial 
necrosis but this troponin increase is not necessarily due to atherosclerotic coronary 
artery disease (8). Therefore, myocardial infarction should be diagnosed in 
conjunction with other supportive evidence.  
Myonecrosis can be a result of a number of other clinical situations with cardiac and 
non-cardiac etiologies (10-12). respectively named in Table 1 but they will be 
commented later.  
 
In this paper three patients with “non- ischemic” causes of elevated troponin will be 
discussed. Thus, with absent angiographicly significant coronary artery disease.  
 
Figure 1. Troponin 
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Table 1. Possible etiologies of elevated troponin in patients with normal coronary 
angiography 
 
 
Direct 
damage to 
myocardium 
Diminshed 
oxygen 
supply to 
myocardium 
Increased 
oxygen demand 
Increased 
demand and 
diminished 
supply 
Other causes 
Inflammation 
(either 
myocarditis or 
pericarditis) 
Coronary 
embolus 
Left ventricular 
hyperthrophy 
Tachycardia 
and severe 
AS 
Infiltrative 
disease of 
myocardium 
Electrical 
discharge  
shock cardiomyopathy Tachycardia 
associated 
with bleeding 
Renal failure 
Mechanical 
damage  
GI bleeding COPD  sepsis hypothyrodism 
Chemical 
damage  
Anemia Valvular lesion Severe CHF False positive 
troponin (RA, 
cirrhosis) 
 Coronary 
spasm 
SVT  Diabetic 
ketoacidosis 
 Hypercoagua
lable state 
Extreme 
endurance 
excersise 
 Scorpion toxin 
 Aortic 
dissection 
Increased 
sympathetic 
activity 
  
 Coronary 
dissection 
ASD failure 
associated with 
RV dilation  
  
 
(13-20) 
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2. METHODS 
 
2.1 Data assessment 
 
Data was assessed retrospectively from medical files and databases collected in 
2014 at KBC Zagreb. Patients who were considered for this study were patients who 
underwent coronary angiography in 2014 at KBC Zagreb due to suspicion of ACS, 
and patients who had troponin-positive “chest pain”. This involved a total of 976 
patients who underwent cardiac catheterization within 48h of admission in the 
aforementioned year. 
 
2.2 Exclusion criteria 
 
Exclusion criteria was coronary arterial luminal stenosis greater than 30%, and 
missing medical data. 
 
2.3. Evaluation of patients  
 
Upon arrival, Troponin T was determined immediately and at 8, and 12 h after the 
onset of pain, but peak Troponin T values were used for the purpose of this research. 
The high-sensitive cTnT (hs-cTnT) assay was used to detect the presence of 
troponin in serum. This assay is a modification of the fourth-generation cTnT assay 
and is significantly improved (21). This new type of cTnT assay further reduces the 
susceptibility for false “positive” troponin.  
Troponin T increase was defined as >0.014 ng/mL (14 ng/L) (cut off value).  
Within 24 h from admission, routine CRP was measured. Concentration >5 ng/ml 
was considered elevated.  
Creatinine is determined by enzymatic colorimetric assay. Cut-off value for male was 
105 umol/l, and for females 85umol/l.  
Serum value of Creatinine Kinase was measured using an enzymatic rate method of 
foregoing reaction catalyzed by Creatinine Kinase. Normal reference range is 0-177 
u/L. 
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Creatinine Kinase activites are greatest in skletal muscles, followed by the heart, 
brain, and other tissue (22). 
 
Chest pain unit protocol was used to evaluate patients (23).  
It was consisted of the clinical history (also to establish risk factors for atherosclerotic 
CAD), physical examination, ECG, echocardiography and coronary angiography.  
 
2.4 Diagnostic criteria  
   
2.4.1. Takotsubo syndrome 
 
The diagnosis of Takotsubo syndrome, stress cardiomyopathy, was diagnosed based 
on presence of all defined criteria: 
1. Transient hypokinesis, akinesis, or dyskinesis in the left ventricular mid 
segments with or without apical involvement; regional wall motion 
abnormalities that extend beyond a single epicardial vascular distribution; and 
a stressful trigger 
2. the absence of obstructive coronary disease or angiographic evidence of 
acute plaque rupture  
3. new ECG abnormalities (ST-segment elevation and/or T-wave inversion) or 
modest elevation in cardiac troponin  
4. the absence of pheochromocytoma and myocarditis (24). 
 
2.4.2. Shock 
 
Shock was established when despite pharmacologic and mechanical support systolic 
blood pressure remained below 80mmHg or cardiac index was below 2 l/min/m2.  
 
2.4.3. Pulmonary embolism  
 
Pulmonary embolism was established when there was dyspnea or pleuritic chest 
pain present and ECG changes (S1Q3T3).  
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2.4.4.  Hypertensive heart disease  
 
Hypertensive heart disease was diagnosed based on clinical picture, and ventricular 
hypertrophy and diastolic dysfunction based on echocardiography (25).   
 
2.4.5 Tachycardia 
 
A ventricular response greater than 100/bpm was defined as tachycardia.  
 
2.4.6. Malignant disease progression 
 
Diagnosis of severe critical illness was documented in this paper as progressed 
gastric carcinoma.  
 
2.4.7. Hypertensive crisis 
 
Hypertensive crisis was diagnosed when there was a systolic pressure greater than 
180mmHg and/or diastolic pressure greater than 110mmHg, with associated acute 
end-organ damage (26). 
 
2.4.8. Pulmonary hypertension 
 
Pulmonary hypertension was defined when mean pulmonary arterial pressure ≥25 
mmHg at rest confirmed by right heart catheterization.  
 
2.4.9. Atrial fibrillation 
 
Atrial fibrillation was defined when ECG findings included oscillatory or fibrillatory 
waves of different sizes replacing normal consistent P waves, with rapid ventricular 
response, greater than 90 beats per minute.  
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3. RESULTS 
 
3.1. Coronary angiography in KBC Zagreb 
 
Total of 2530 patients in 2014 at KBC Zagreb underwent coronary angiography due 
to different indications, which are respectively named in Table 2.  
976 (38.6%) patients had troponin positive “chest pain” and consequently had 
suspicion for ACS.  Of the total 976 patients with suspicion of ACS, 30 (3.1%) had 
potential alternative cause for myocyte injury.  
The average of serum troponin T in patients without ACS or any other significant 
CAD was 0.41 ng/l. The lowest measured value was 0.016ng/l, and the highest 
measured troponin value in patients with normal coronary angiography was 2.28 ng/l. 
Average Troponin T concentration obtained in serum was 0.90 ng/l.  
Furthermore, patients who were diagnosed with STEMI and NSTEMI had 
significantly higher values of troponin in serum.  
 
Table 2. Indications for coronary angiography in 2014 in KBC Zagreb 
 
Indication  % of patients 
(n=2530) 
Stable angina 22.94 
ACS with ST-elevation and increased troponin 14.93 
ACS without ST-elevation and increased troponin 11.70 
Unstable angina 10.93 
Post-transplant evaluation 6.62 
ACS with ST-elevation and normal troponin 6.51 
Ischemic heart disease screening 4.66 
Elective PCI 4.20 
PCI control 4.00 
Pre-operative evaluation 3.96 
Valvular heart disease evaluation 3.85 
Cardiomyopathy 3.27 
Cardiac arrest 0.89 
Rhythm abnormality 0.89 
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Subacute STEMI   0.77 
Post-operative evaluation 0.69 
Pre transplantation evaluation 0.65 
Post CABG evaluation 0.65 
ACS without ST- elevation and normal troponin 0.62 
VT 0.50 
HOCM 0.46 
Atypical chest pain 0.42 
Congenital heart disease 0.38 
Temporary pacemaker 0.35 
TAVI assessment 0.31 
Cardiogenic shock 0.31 
Positive stress test 0.31 
CABG assessment 0.27 
Aortic aneurysm 0.27 
Positive SPECT 0.27 
Heart failure 0.23 
Pericarditis 0.23 
PTSMA 0.19 
In-stent restenosis 0.19 
CTO 0.19 
Recent myocardial infarction 0.15 
Myocarditis 0.15 
Endocarditis 0.12 
Subchronic STEMI 0.12 
Chest pain 0.12 
Stent thrombosis 0.12 
Diascopy 0.08 
Fibrinolyzed chronic myocardial infarction 0.04 
CVI 0.04 
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3.2. Laboratory results 
 
Of the total 976 patients with suspicion of ACS, 30 (3.1%) patients had alternative 
causes for myocyte injury. CRP was measured in all 30 patients, and in 15 (50%) 
was found to be raised. The lowest «positive» detected concentration was 6.9 mg/L, 
and highest measured CRP value was 73,7 mg/L. 
Creatinine Kinase was found to be raised in 12 patients (40%) with normal coronary 
angiography. The average was 228.7 U/L, with lowest value being 31 U/L and the 
highest 859 U/L. 
Creatinine lowest measured value was 39 μmol/L and highest measured value was 
124 μmol/L. The average was 72 μmol/L. 
 
3.3 Clinical presentation 
 
The most common complaint found among these patients was chest pain. 
Classification of chest pain described in those patients is given in Table 3.  
 
Table 3. Types of chest pain in patients with elevated troponin and normal coronary 
angiography 
 
Type of chest pain % of patients (n=30) 
Typical 43.3 
Atypical 30.0 
Non-anginal pain 26.7 
Typical features include:  
1. Retrosternal location of discomfort (in whole or in part)  
2. Provocation by activity or stress  
3. Relief by rest or nitroglycerin  
If all three features are present the chest pain or discomfort is classified as TYPICAL 
ANGINAL PAIN. If two of three features are present the chest discomfort is classified as 
ATYPICAL ANGINAL PAIN. If only one of three features are present, the chest discomfort is 
classified as NON ANGINAL CHEST PAIN (9, 23). 
 
9 
 
Other clinical presentations found in patients with troponin-positive “chest pain” are 
given in Table 4. 
 
Table 4. Clinical presentations of patients with elevated troponin and normal 
coronary angiography 
 
Other clinical presentations % patients (n=30) 
Dyspnea  33.3 
Nausea 13.3 
Tingling in arms or hands 13.3 
Night sweats 10.0 
Palpitations 10.0 
Dry cough 6.7 
Vertigo  6.7 
General weakness 3.3 
dysphagia 3.3 
 
3.4. Comorbidities and risk factors 
 
The majority of patients with troponin positive “chest pain” have history of risk factors 
and comorbidities, which increase risk for further cardiovascular events (table 5). 
 
Table 5. Comorbidities and risk factors 
 
Comorbidity % of patients (n=30) 
Hypertension 70 
Hypercholesterolemia 53 
Smoking 30 
History of ACS 23 
DM 2 23 
CHF 23 
COPD 13 
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3.5. Etiology of myonecrosis with normal coronary arteries  
 
The most common cause identified was hypertensive crisis, followed by Takotsubo 
syndrome. Others causes include pulmonary embolism, AF, cardiogenic shock, 
COPD exacerbation, malignant disease progression, severe aortic stenosis, 
persistent ventricular tachycardia, pulmonary hypertension, severe aortic stenosis, 
advanced heart failure, and in two patients no precipitants for increased troponin 
were identified (Table 6).  
 
Table 6. The causes of elevated Troponin in observed patients 
 
Dx % of patients (n=30) 
Hypertensive crisis or urgency 20.00 
Takotsubo syndrome 16.67 
AF 10.0 
COPD exacerbation 10.0 
Inconclusive 10.0 
Moderate to severe AS 6.67 
Advanced heart failure 6.67 
Pulmonary hypertension 3.33 
Hypertensive cardiomyopathy 3.33 
Acute pulmonary embolism 3.33 
Malignant disease progression 3.33 
Cardiogenic Shock                                        3.33 
VT                                                                 3.33 
 
3.6. ECG findings 
 
All of electrocardiogram findings are given in Table 7.  ST elevations were common 
in patients diagnosed with Takotsubo syndrome negative T waves were most 
commonly seen with hypertensive crisis (Table 7). 
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Table 7. ECG findings 
 
ECG findings % Patients (n=30) 
T inversion 23.3 
ST-elevation (more than 0.05 mV) 20.0 
No changes 16.7 
AF 13.3 
RBBB 13.3 
P pulmonale  10.0 
S1Q3T3 3.3 
 
 
Patient 1 
 
A 44 year old nonsmoker, with negative family history of ischemic heart disease was 
admitted to KBC Zagreb from Opća bolnica Bjelovar due to suspicion of STEMI. Her 
other comorbidities are arterial hypertension (controlled), hypercholesterolemia (well 
controlled), obesity and depression. Her 12- lead ECG showed ST elevations 
(around 1mm) in inferolateral leads. Her RR was 140/75 mmHG. Troponin T levels 
were raised at 1.36 μg/L, CRP was 6.9mg/l, CK MB 433 U/L, and creatinine was 
75umol/l.  
Patient underwent examination with echocardiography were ballonings and akinetic 
apex were seen. EF was measured 50% by Teicholz method.  
The patient underwent coronary angiography. Figure 2.a and 2.b illustrate the normal 
appearance of right and left coronary arteries, but on ventriculogram an anteroapical 
akinesia of LV was obtained suggesting that the cause of raised troponin is stress 
cardiomyopathy – Takotsubo syndrome (Figure 3). Patient was discharged with beta 
blockers, statins and advised to follow a strictly diet.  
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Figure 2.a Coronarogram of LAD                    Figure 2.b Coronarogram of RCA 
       
 
 
                                    Figure 3.  Ventriculogram 
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Patient 2  
 
A 73-year-old smoker, hypercolesterolemic, and hypertensive (180/110mmHg) came 
to the emergency department with a chief complaint of typical chest pain and 
accompanied felling of shortness of breath. In 2013 she was diagnosed with 50% 
stenosis of internal carotid artery. Peak troponin T measured during her hospital stay 
was 0.065 μg/L, CRP was 0.4 mg/L, CK 119 U/l, and creatinine at 84 μmol/L. Her 12-
lead ECG showed negative T waves in lead aVL.  
The angiogram did not show any significant coronary artery stenosis, only torturous 
coronary arteries. On echocardiography moderate to severe AS was confirmed. 
Patient got conservative therapy and antihypertensive medication, which ease her 
symptoms and signs. She was diagnosed with hypertensive urgency and moderate 
to severe AS. She was discharged with beta blockers, Aspirin, diuretics, 
antihypertensive medication, and statins.  
 
 
Patient 3 
 
A 57-years old heavy smoker, dyslipidemic with elevated blood pressure (170/110 
mmHg) came to emergency department in KBC Zagreb with a chief complaint of 
persistent typical chest pain. Other complaints were blurred vision, epistaxis, and 
severe headache.  In the history there were no other comorbidities identified. Peak 
troponin T measured was 0.902 μg /l, CRP was 2.9 mg/L, CK 859 U/L, creatinine 
was 88 μmol/L. His 12- lead ECG did not show any changes.  
Cardiac catheterization did not show any significant CAD, only less than 30% 
stenosis of LCX. Echocardiogram showed that there was minor to moderate septal 
hypertrophy, with normal systolic function. He was diagnosed with hypertrophic 
cardiomyopathy. The patient was given Nitrate, but he claimed that the intensity of 
his chest pain did not change. After 3 days the patient was released with a diagnosis 
of hypertensive heart disease with diastolic dysfunction. He was released with a 
therapy including statins, ACE inhibitors, anti aggregation therapy, Aspirin and also 
was advised to follow a strict diet to control his lipid levels. He was advised to see his 
cardiologist in 6 months and to repeat all diagnostic procedures. 
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4. DISCUSSION 
 
In this paper, 30 (3.1%) patients in 2014 in KBC Zagreb with troponin-positive chest 
pain and suspicion of ACS, were considered not to be related to  angiographically 
significant coronary artery disease.  
 
Values of troponin increase were not so useful in diagnosing ACS, and cardiac 
diagnostic procedure, echocardiography was frequently abnormal in patients without 
ACS or significant coronary artery disease.  
Various cardiac and non-cardiac conditions have been described to cause the 
increase of troponin, in the absence of criteria to diagnose ACS (5-7,12-20, 24-25).  
 
Mechanisms causing elevation of troponin, whether it is due to ACS or some other 
mechanism is of major therapeutic importance. Unnecessary coronary angiograms 
may not be appropriate in some of these patients. Increased troponin and absence of 
typical presentation of ACS, presents a diagnostic challenge. Patients who were 
reviewed in this paper, all had alternative etiology causing elevation of troponin, 
although the mechanism causing it in some cases was unclear.  
 
Troponin may arise as a result of mismatch between myocardial oxygen supply and 
demand, as a result of direct damage, and also irreversible myocyte injury can cause 
an initial release of cytosolic troponin, in contrast to reversible injury which causes 
release of factors which lead to increased permeability of the membrane and leakage 
of degraded free troponin without myocyte necrosis (27). 
 
Some cases involved true myocyte necrosis, which was related to increased oxygen 
demand in the absence of an appropriate supply (10). Furthermore, epicardial 
luminal stenosis is more likely to cause such a mismatch. In addition, some studies 
describe it in patients without evidence of coronary impairment (5, 10).  
A good example of mismatch is hypertensive crisis, which was observed in most of 
the patients reviewed (28).  
Strenuous exercise, catecholamine release and stress-related neuropeptides (last 
two most commonly seen in Takotsubo syndrome) are also documented causes (24, 
29).  
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Tachycardia can also result in increase of troponin because there is a decreased 
time available for diastolic coronary perfusion (31). Alteration in the ST segment 
during episodes of tachycardia are not necessary indications for the presence of 
ischemia (32). Troponin elevation and the rate and duration of tachycardia, however 
shown no connections in between them (31, 32). 
Toxic cytokines, ongoing apoptosis, chronic ischemia, and loss of cell membrane 
integrity can all cause elevation of troponin in patients with heart failure (33, 34). In 
addition, ongoing loss of viable cardiac myocytes, which is characteristic for 
progressive heart failure explains elevation of troponin (35). 
In patients with moderate-to-large pulmonary embolism or massive pulmonary 
embolism elevation of troponin has been observed. It can be a result of increase in 
right ventricular myocardial oxygen demand, which may lead to right ventricular 
dilation and ischemia (36). 
Exaggerated inflammatory response, as it is seen in patients with COPD 
exacerbation can also predispose for myocardial injury (37). In those patients 
elevated troponin is a strong predictor of in-hospital death in patients who are 
admitted for COPD exacerbation (38). 
Ischemia can also be result of impaired coronary flow reserve caused by combination 
of the ventricular hypertrophy, tachycardia, and lower perfusion pressure, all which 
can occur in critical aortic stenosis (39)  
Other conditions causing troponin release in the absence of ACS or significant 
coronary artery disease include conditions that affect myocardial cell metabolism, 
mechanisms that are still unknown, and also it was observed in patients with 
malignant disease progression.  
 
To conclude everything that has been learnt doing research for this paper is that an 
elevated troponin can be a prognostic value in certain non-ischemic causes. 
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5. CONCLUSION 
 
Absence of angiographically significant coronary disease, excludes ACS as a cause 
of elevated troponin.  
 
This small group of observed patients with elevated troponin due to diverse etiology 
requires further investigation of the mechanism, which causes an elevation of 
troponin and risk stratification.  
 
Biochemical investigation with use of Troponin T as a screening method in patients 
with etiology other than ACS should be discouraged.  
 
Troponin is not so useful to “rule in” ACS due to lack of its specificity, but it is a 
sensitive biomarker to “rule out” non-ST-segment elevation myocardial infarction. 
 
Inappropriate therapy and delays in definitive diagnosis and treatment may be 
observed in such a patients because of misleading positive troponin. 
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